YOLFTbeta
Imeik Technology Development Co

Imeik Technology Development Co

300896 · SHE · Healthcare / Medical Instruments & Supplies

85.55CNY-0.41 (-0.48%)

Price History

Full chart

Market Stats

Previous Close85.96
Open85.55
Day Range85.23 – 86.95
52-Week Range82.46 – 178.80
Volume1.81M
Market Cap28.75B
P/E (TTM)26.17
Forward P/E17.76
EPS3.63
Dividend Yield1.89%
Beta0.59
50-Day Avg96.90
200-Day Avg115.67

About

Imeik Technology Development Co.,Ltd. engages in the research and development, and transformation of biomedical materials and biopharmaceutical products in China. The company offers aesthetic medicine products, such as cross-linked sodium hyaluronate gel with PLLA-b-PEG microsphere; poly facial implant thread; medical sodium hyaluronate-hydroxypropyl methylcellulose gel; sodium hyaluronate composite solution for injection; modified sodium hyaluronate gel for injection; medical PVA gel ball-sodium hyaluronate-hydroxypropyl methylcellulose gel; and skin care products. It serves medical aesthetic institutions. The company was incorporated in 2004 and is headquartered in Beijing, China.

Company Details

  • SectorHealthcare
  • IndustryMedical Instruments & Supplies
  • CEOMr. Yifeng Shi
  • Employees1.46K
  • HeadquartersShimao Building, Beijing, China, 100022, China
  • Websitehttps://www.imeik.net/cn/

Leadership

  • Mr. Yifeng ShiGM & Director · b. 1974
  • Mr. Renchao ZhangChief Financial Officer · b. 1979
  • Liu DanAccounting Supervisor
  • Ms. Dong Mei LiDeputy GM & Board Secretary · b. 1984

Financials

Income Statement

Currency: CNY2014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue75.12M111.82M140.73M222.49M321.01M557.72M709.29M1.45B1.94B2.87B3.03B2.42B
Growth (%)-+48.84%+25.86%+58.09%+44.28%+73.74%+27.18%+104.13%+33.91%+47.99%+5.45%-19.89%
Cost of Revenue5.03M10.53M18.50M30.82M34.94M41.12M58.14M91.28M99.91M140.77M162.22M237.28M
Gross Profit70.09M101.29M122.23M191.67M286.07M516.60M651.15M1.36B1.84B2.73B2.86B2.19B
Gross Margin93.30%90.59%86.86%86.15%89.12%92.63%91.80%93.70%94.85%95.09%94.64%90.21%
Operating Expense37.02M74.11M60.23M97.97M142.81M166.38M148.41M229.97M350.73M570.37M572.93M870.74M
Operating Income33.07M27.18M62.01M93.70M143.27M350.21M502.74M1.13B1.49B2.16B2.29B1.32B
Operating Margin44.03%24.31%44.06%42.11%44.63%62.79%70.88%77.81%76.76%75.22%75.70%54.29%
EBITDA35.01M28.66M64.89M96.25M151.48M360.84M513.70M1.13B1.51B2.19B2.31B1.39B
EBITDA Margin46.61%25.63%46.11%43.26%47.19%64.70%72.42%78.38%77.65%76.25%76.43%57.40%
Net Income28.42M17.65M53.38M82.19M122.85M305.52M439.75M957.98M1.26B1.86B1.96B1.29B
Net Income Margin37.83%15.79%37.93%36.94%38.27%54.78%62.00%66.16%65.17%64.77%64.70%53.26%
R&D4.43M5.73M13.08M28.49M33.68M48.56M61.80M102.31M173.11M250.13M303.68M335.72M
R&D as % of Total Revenue5.89%5.12%9.29%12.81%10.49%8.71%8.71%7.07%8.93%8.72%10.04%13.85%
Interest Expense--0113.80K351.00K062.96K2.14M3.46M3.22M2.87M7.80M
Interest Expense % of Total Revenue--0.00%0.05%0.11%0.00%0.01%0.15%0.18%0.11%0.09%0.32%

Balance Sheet

Currency: CNY2014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets105.29M172.64M313.86M396.41M463.61M743.65M4.67B5.27B6.26B6.85B8.34B8.91B
Total Liabilities17.23M20.98M48.36M68.09M58.87M80.95M140.45M242.31M312.77M367.32M390.37M743.43M
Total Equity88.06M151.66M262.87M325.06M398.41M658.93M4.53B5.03B5.85B6.35B7.80B7.58B
Cash32.02M49.39M155.99M214.35M265.55M505.61M3.46B3.26B3.14B2.43B1.51B1.23B
Total Debt--2.07M5.51M1.97M-39.00M40.19M48.39M37.46M26.01M10.01M
Net Debt-32.02M-49.39M-153.92M-208.84M-265.55M-505.61M-3.42B-3.22B-3.09B-2.40B-1.49B-1.22B

Cash Flow

Currency: CNY2014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow27.95M48.35M55.00M84.16M135.50M309.72M425.68M942.78M1.19B1.95B1.93B1.39B
Investing Cash Flow-38.92M-48.54M-11.19M-11.10M-38.41M-25.62M-916.25M-647.78M-943.71M-1.28B-2.36B-502.10M
Financing Cash Flow-17.57M60.50M-12.40M-45.89M-44.03M3.44B-487.30M-374.18M-1.38B-490.13M-1.13B
Capital Expenditure4.94M11.61M54.34M42.59M39.16M32.60M32.11M23.03M155.68M63.68M239.24M170.70M
Free Cash Flow23.01M36.74M662.27K41.57M96.34M277.12M393.57M919.75M1.04B1.89B1.69B1.22B
Dividends Paid---20.22M49.68M45.00M420.70M420.70M454.36M1.00B499.90M1.51B
FCF to OCF82.32%75.99%1.20%49.39%71.10%89.48%92.46%97.56%86.96%96.74%87.59%87.69%
Dividend Paid to FCF---48.65%51.57%16.24%106.89%45.74%43.76%53.15%29.62%123.93%

Earnings

Report DateOct 28, 2020Feb 8, 2021Apr 26, 2021Aug 23, 2021Oct 14, 2021Mar 7, 2022Apr 26, 2022Aug 24, 2022Oct 25, 2022Mar 8, 2023Apr 25, 2023Aug 24, 2023Oct 24, 2023Mar 19, 2024Apr 24, 2024Aug 22, 2024Oct 23, 2024Mar 21, 2025Apr 24, 2025Aug 18, 2025Oct 28, 2025Mar 19, 2026Apr 22, 2026Aug 20, 2026
EPS Estimate-------1.431.361.961.321.582.302.001.711.691.821.561.791.811.180.911.051.19
EPS Actual0.660.711.241.181.311.151.291.441.301.251.281.812.102.051.741.871.461.151.331.070.850.420.990.98
Surprise-------0.70%-4.41%-36.22%-3.03%14.56%-8.70%2.50%1.75%10.65%-19.78%-26.28%-25.70%-40.88%-27.97%-53.85%-5.71%-17.65%
TimingPre-marketAfter-hoursPre-marketPre-marketAfter-hoursPre-marketAfter-hoursPre-marketAfter-hoursAfter-hoursPre-marketPre-marketAfter-hoursAfter-hoursAfter-hours-Pre-market-Pre-marketPre-marketPre-marketAfter-hoursPre-marketPre-market

Key Statistics & Ratios

Market Cap28.75B
Enterprise Value24.62B
Trailing P/E26.17
Forward P/E17.76
PEG Ratio0.96
Price / Sales12.13
Price / Book3.58
EPS3.63
Book Value26.25
Revenue (TTM)2.37B
Gross Profit (TTM)2.18B
EBITDA1.15B
Profit Margin46.22%
Operating Margin49.26%
Return on Equity13.44%
Return on Assets7.74%
Shares Outstanding302.59M
Shares Float129.03M
Beta0.59
Dividend Yield1.89%
Dividend Rate1.80
Payout Ratio55.56%

Dividends

20262×
1.00Sep 3, 20260.80Apr 29, 2026
20252×
1.20Sep 26, 20253.80Apr 30, 2025
20241×
1.66Apr 29, 2024
20232×
1.32Oct 23, 20232.00May 15, 2023
20221×
1.50Apr 18, 2022
20211×
1.39Mar 16, 2021

Stock Splits

  • Apr 29, 20241.4:1
  • Mar 16, 20211.8:1